Literature DB >> 31600807

Rapid Centrifugation in the Routine Hemostasis Laboratory.

Nathan Wolfensberger1, Georgios Georgiou2, Evelyne Giabbani3, Marianne Reusser3, Linet M Njue3, Martin Fiedler4, Alexander B Leichtle4,5, Michael Nagler3,4.   

Abstract

BACKGROUND: The use of short and uniform centrifugation schemes contributes significantly to the successful automation of laboratory procedures. It is however unclear if this is applicable to the hemostasis laboratory.
OBJECTIVES: This article assesses the accuracy of measurements obtained with a rapid, high-speed centrifugation scheme in a large set of hemostasis tests, covering the full spectrum of values obtained in clinical practice, and using meaningful statistical measures.
METHODS: Two citrated plasma samples were obtained from consecutive patients of a tertiary hospital with suspected abnormal hemostasis tests and processed with two centrifugation schemes in parallel: 1,500 × g for 10 minutes and 3,137 × g for 7 minutes. The following tests were conducted: prothrombin time (n = 125), international normalized ratio (n = 146), activated partial thromboplastin time (n = 119), thrombin time (n = 105), fibrinogen (n = 125), factor (F)II (n = 69), FV (n = 64), FVII (n = 64), FX (n = 67), FVIII (n = 55), FIX (n = 37), FXI (n = 35), and FXIII (n = 20), D-dimer (n = 34), antithrombin (n = 31), anti-Xa activity (n = 30), von Willebrand antigen (n = 25), and von Willebrand activity (VWF:GPIbM; n = 27).
RESULTS: A wide range of results were obtained in all tests. Spearman's rank correlation coefficient was at least 0.95 for all tests except FV, FIX, and FXI. The coverage probability π at a given deviation index κ of 15% was above 0.9 for all tests except FV, FVII, FX, FVIII, FIX, FXI, and VWF:GPIbM, suggesting a lack of agreement.
CONCLUSION: Our results suggest that high-speed centrifugation is applicable to the majority of routine hemostasis parameters. The coverage probability was more sensitive than Spearman's rank correlation to detect disagreement among centrifugation schemes. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31600807     DOI: 10.1055/s-0039-1696712

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers.

Authors:  Mirjam Kolev; Michael P Horn; Nasser Semmo; Michael Nagler
Journal:  J Transl Autoimmun       Date:  2022-03-06

2.  Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study.

Authors:  Vepusha Sathanantham; Lorenzo Alberio; Cédric Bovet; Pierre Fontana; Bernhard Gerber; Lukas Graf; Adriana Mendez; Thomas C Sauter; Adrian Schmidt; Jan-Dirk Studt; Walter A Wuillemin; Michael Nagler
Journal:  Life (Basel)       Date:  2022-07-11

3.  Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study.

Authors:  Michael P Horn; Hulda R Jonsdottir; Daniel Brigger; Lauro Damonti; Franziska Suter-Riniker; Olga Endrich; Tanja K Froehlich; Martin Fiedler; Carlo R Largiadèr; Jonas Marschall; Benjamin Weber; Alexander Eggel; Michael Nagler
Journal:  Allergy       Date:  2022-01-11       Impact factor: 14.710

4.  Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study.

Authors:  Daniel Brigger; Michael P Horn; Luke F Pennington; Abigail E Powell; Denise Siegrist; Benjamin Weber; Olivier Engler; Vanja Piezzi; Lauro Damonti; Patricia Iseli; Christoph Hauser; Tanja K Froehlich; Peter M Villiger; Martin F Bachmann; Stephen L Leib; Pascal Bittel; Martin Fiedler; Carlo R Largiadèr; Jonas Marschall; Hanspeter Stalder; Peter S Kim; Theodore S Jardetzky; Alexander Eggel; Michael Nagler
Journal:  Allergy       Date:  2020-11-13       Impact factor: 14.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.